Listed

PharmaCyte Biotech, Inc.: Form 10-Q for the period ended Oct 31, 2012

Filed with the SEC on Dec 26, 2012 and accepted by EDGAR at Dec 26, 2012, 16:46 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2012-10-31. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2012-08-01 to 2012-10-31$6.3kus-gaap:Revenues
Revenue6 months2012-05-01 to 2012-10-31$12.9kus-gaap:Revenues
Cost of revenue3 months2012-08-01 to 2012-10-31$9.6kus-gaap:CostOfRevenue
Cost of revenue6 months2012-05-01 to 2012-10-31$9.6kus-gaap:CostOfRevenue
Gross profit3 months2012-08-01 to 2012-10-31−$3.3kus-gaap:GrossProfit
Gross profit6 months2012-05-01 to 2012-10-31$3.3kus-gaap:GrossProfit
Operating income3 months2012-08-01 to 2012-10-31−$348.8kus-gaap:OperatingIncomeLoss
Operating income6 months2012-05-01 to 2012-10-31−$887.6kus-gaap:OperatingIncomeLoss
Interest expense3 months2012-08-01 to 2012-10-31$67.3kus-gaap:InterestExpense
Interest expense6 months2012-05-01 to 2012-10-31$113.3kus-gaap:InterestExpense
Net income3 months2012-08-01 to 2012-10-31−$382.8kus-gaap:NetIncomeLoss
Net income6 months2012-05-01 to 2012-10-31−$893.3kus-gaap:NetIncomeLoss
Basic EPS3 months2012-08-01 to 2012-10-31$0.00us-gaap:EarningsPerShareBasic
Basic EPS6 months2012-05-01 to 2012-10-31$0.00us-gaap:EarningsPerShareBasic
Operating cash flow6 months2012-05-01 to 2012-10-31−$169.9kus-gaap:NetCashProvidedByUsedInOperatingActivities
Cash and equivalentsAt period end2012-10-31$22.7kus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2012-10-31$1.3mus-gaap:AssetsCurrent
Total assetsAt period end2012-10-31$2.3mus-gaap:Assets
Current liabilitiesAt period end2012-10-31$3.5mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2012-10-31$3.8mus-gaap:Liabilities
Shareholders' equityAt period end2012-10-31−$2.1mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001445305-12-003886. Last ingested by Listed: Nov 14, 2026, 20:52 ET. Listed shows no prices and gives no investment advice.